Genotyping human polymorphic arylamine n-acetyltransferase: Identification of new slow allotypic variants

Pharmacogenetics

Volumn 2, Issue 5, 1992, Pages 217-226

  Hickman, Dean ^a   Risch, Angela ^a   Camilleri, Jeremy P ^b   Sim, Edith ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; DNA; PENICILLAMINE;

ADULT; AGED; ALLELE; ARTICLE; ENZYMOLOGY; GENE AMPLIFICATION; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; IATROGENIC DISEASE; METABOLISM; MOLECULAR CLONING; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROTEINURIA;

ADULT; AGED; ALLELES; ARYLAMINE N-ACETYLTRANSFERASE; BASE SEQUENCE; CLONING, MOLECULAR; DNA; GENE AMPLIFICATION; GENOTYPE; HUMAN; MIDDLE AGE; MOLECULAR SEQUENCE DATA; PENICILLAMINE; POLYMERASE CHAIN REACTION; POLYMORPHISM (GENETICS); PROTEINURIA; SUPPORT, NON-U.S. GOV'T;

EID: 0026935909     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199210000-00004     Document Type: Article

References (28)

1. Blum M, Grant DM, McBride W, Heim M, Meyer UA. Human arylamine N-acetyltransferase genes: isolation, chromosomal localisation, and functional expression. DNA Cell Biol 1990: 9, 193-203.
2. Blum M, Demierre A, Grant DM, Heim M, Meyer UA. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA 1991: 88, 5237-5241.
3. Bulovskaya UN, Krupkin RG, Bochina TA, Shipkova AA, Pavlova MV. Acetylator phenotype in patients with breast cancer. Oncology 1978: 35, 185-188.
4. Cartwright RA, Glasham RW, Rogers HJ, Ahmed RA, Hall DB, Higgins E, Kahn MA. The role of N-acetyltransferase phenotypes in bladder carcinogenesis: A pharmaco-genetic epidemiological approach to bladder cancer. Lancet 1982: 2, 842-846.
5. Coroneos E, Gordon JW, Kelly SL, Wang PD, Sim E. Drug metabolising N-acetyltransferase activity in human cell lines. Biochim Biophys Acta 1991: 1073, 593-599.
6. Deguchi T, Mashimo M, Suzuki T. Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N- acetyltransferase in human liver. J Biol Chem 1990: 265, 12757-12760.
7. DiLella AG, Woo SLC. Cloning large segments of genomic DNA using cosmid vectors. Methods in Enzymology 1987: 152, 199-212.
8. Evans DAP. N-acetyltransferase. Pharmacol Ther 1989: 42, 157-234.
9. Evans DAP, White TA. Human acetylation polymorphism. J Lab Clin Med 1963: 63, 394-403.
10. Grant DM, Morike K, Eichelbaum M, Meyer UA. Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J Clin Invest 1990: 85, 968-972.
11. Hearse DJ, Weber WW. Multiple N-acetyltransferases and drug metabolism: tissue distribution, characterization and significance of mammalian N-acetyltransferase. Biochem J 1973: 132, 519-526.
12. Hein DW, Weber WW. Metabolism of procainamide, hydralazine, and isoniazid in relation to autoimmune(-like) reactions. In: Kammuller ME, Bioksma N, Seinen W, eds. Autoimmunity and toxicology. Amsterdam Elsevier Science Publishers. 1989: 239-265
13. Helmke K, Scheuermann R, Boeder T, Federlin, F. Clinical and prognostic significance of antinuclear antibodies in patients treated with D-penicillamine. In: Maini RN, Berry H, eds. Modulation of autoimmunity and disease-The penicillamine experience: New York: Praeger Press, 1981: 45-49.
14. Hickman D, Sim E. N-acetyltransferase polymorphism: comparison of phenotype and genotype in Humans. Biochem Pharmacol 1991: 42, 1007-1014.
15. Ilett KF, David BM, Detchon P, Castleden WM, Kwa R. Acetylation phenotype in colorectal carcinoma. Cancer Res 1987: 47, 1466-1469.
16. Jenne JW, Orsen M. Partial purification and properties of the isoniazid transacetylase in human liver. Its relationship to the acetylation of para-aminosalicylic acid. J Clin Invest 1965: 44, 1992-2002.
17. Kelly SL, Sim E. Expression of N-acetyltransferase in a human monocytic cell-line, U937. Human Exp Toxicol 1991: 10, 33-38.
18. Mandel M, Higa A. Calcium-dependent bacteriophage DNA infection. J Mol Biol 1970: 53, 159-162.
19. Mommsen S, Barford NM, Aagaard J. N-Acetyltransferase phenotypes in the urinary bladder carcinogenesis of a low risk population. Carcinogenesis 1985: 6, 199-201.
20. Ohsako S, Deguchi T. Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltrans- ferases from human liver. J Biol Chem 1990: 265, 4630-4634.
21. Perry HM. Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis. Am J Med 1973: 54, 58-72.
22. Philip PA, Rogers HJ, Millis RR, Rubens RD, Cartwright RA. Acetylator status and its relationship to breast cancer and other diseases of the breast. Eur J Cancer Clin Oncol 1987: 23, 1701-1706.
23. Reidenberg MM, The chemical induction of systemic lupus erythematosus and lupus-like illness. Arth Rheum 1981: 24, 1004-1009.
24. Rubin RL. Autoimmune reactions induced by procainamide and hydralazine. In: Kammuller ME, Bloksma N, Seinen W, eds. Autoimmunity and toxicology. Amsterdam: Elsevier, 1989: 119-150.
25. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning (A laboratory manual), 2nd edition. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1989.
26. Sim E. Drug-induced immune complex disease. Complement Inflamm 1989: 6, 119-126.
27. Staden R. Searching for patterns in protein and nucleic acid sequences. Methods in Enzymology 1990: 183, 193-211.
28. Vatsis KP, Martell KJ, Weber WW. Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proc Natl Acad Sci USA 1991: 88, 6333-6337.